Kodiak Sciences shares climb over 71% after strong late-stage trial results for eye drug Zenkuda
Kodiak Sciences saw a 71.2% stock increase on 26 March, reaching $38.95, fuelled by successful trial results for Zenkuda, a treatment for diabetic retinopathy. The stock's recent strong performance highlights its potential despite trading below its all-time high.
Kodiak Sciences saw a 71.2% stock increase on 26 March, reaching $38.95, fuelled by successful trial results for Zenkuda, a treatment for diabetic retinopathy. The stock's recent strong performance highlights its potential despite trading below its all-time high.
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
